Introduction {#Sec1}
============

Current guidelines for the management of type 2 diabetes mellitus (T2DM) routinely recommend metformin as first-line therapy in those who are able to tolerate this agent \[[@CR1]\]. However, there are numerous options for second-line therapies for use in combination with metformin in individuals unlikely to achieve their target HbA1c levels with metformin alone. Among these, sulfonylureas are a well-established drug class, but they are typically associated with weight gain and hypoglycemia \[[@CR1], [@CR2]\]. Many patients with T2DM are overweight or obese, and further increases in body weight may be detrimental to their well-being, particularly increasing the risk of cardiovascular disease and microvascular disease \[[@CR3]\].

Sodium glucose co-transporter 2 (SGLT2) inhibitors are another therapeutic class recommended in current guidelines as an option for combination therapy with metformin and are associated with weight loss and a low risk of hypoglycemia \[[@CR1]\]. Canagliflozin is an SGLT2 inhibitor approved for the treatment of adults with T2DM \[[@CR4]\]. Canagliflozin reduces plasma glucose levels by lowering the renal threshold for glucose, thereby increasing urinary glucose excretion \[[@CR5], [@CR6]\]. In a head-to-head study of canagliflozin versus the sulfonylurea glimepiride as add-on to metformin in patients with T2DM, canagliflozin has demonstrated sustained improvements in glycemic control, together with sustained reductions in body weight, over 104 weeks \[[@CR7], [@CR8]\].

In addition to measuring HbA1c in patients with T2DM, there is increasing recognition of the value of using composite endpoints to evaluate T2DM treatments \[[@CR9]\]. Since glycemic control and weight loss are beneficial for most patients with T2DM, this post hoc analysis evaluated the effect of canagliflozin versus glimepiride on reducing both HbA1c and body weight in patients with T2DM inadequately controlled with metformin for up to 104 weeks of treatment.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This post hoc analysis was based on data from a 104-week, randomized, double-blind, active-controlled, non-inferiority, Phase 3 study in patients with T2DM inadequately controlled on metformin. Patients were randomized 1:1:1 to one of the following once-daily treatments: canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride (titrated to a maximum of 6 or 8 mg). The study was conducted at 157 study centers in 19 countries and consisted of a 52-week, double-blind core treatment period, followed by a 52-week, double-blind extension period. Details of the study design have been reported previously \[[@CR7], [@CR8]\].

Briefly, patients were required to be aged 18--80 years and to have inadequately controlled T2DM (HbA1c between 7.0% and 9.5%) while receiving metformin at stable doses of ≥2000 mg/day (or ≥1500 mg/day if unable to tolerate higher doses) for at least 10 weeks. Exclusion criteria included a history of type 1 diabetes; a history of more than one severe hypoglycemia episode (within 6 months); repeated measurements of fasting plasma glucose or fasting self-monitored blood glucose of ≥15.0 mmol/L during the pre-treatment phase; an estimated glomerular filtration rate of \<55 mL/min/1.73 m^2^ (or \<60 mL/min/1.73 m^2^ if based on restriction of metformin use in local label) or serum creatinine concentrations of ≥124 μmol/L for men and ≥115 μmol/L for women; or were taking thiazolidinediones within 16 weeks before screening. Patients were not permitted to use any antihyperglycemic agents, except for metformin, unless pioglitazone was prescribed for rescue therapy. Use of insulin for ≥3 continuous or 7 total days within 3 months of screening was not permitted; however, insulin could be used on up to 2 occasions for no more than 7 consecutive days during the study.

Endpoints {#Sec4}
---------

Change in HbA1c and percent change in body weight from baseline were pre-specified study endpoints. Using individual patient data, the proportion of patients who achieved a decrease from baseline in both HbA1c (%) and body weight (kg) was assessed at Weeks 52 and 104. Safety was assessed based on adverse event (AE) reports. Documented hypoglycemia episodes included biochemically documented episodes (concurrent fingerstick glucose or plasma glucose ≤3.9 mmol/L with or without symptoms) and severe episodes (i.e., requiring the assistance of another individual or resulting in seizure or loss of consciousness).

Statistical Analyses {#Sec5}
--------------------

Analyses were performed using the modified intent-to-treat (mITT) population, which consisted of all randomized patients who received ≥1 dose of study drug. The last observation carried forward (LOCF) approach was used to impute missing data. Efficacy endpoints were analyzed using an analysis of covariance (ANCOVA) model, with treatment, stratification factors, and country as fixed effects and the corresponding baseline value as a covariate.

The least squares (LS) mean differences between groups and 2-sided 95% confidence intervals (CIs) were estimated for changes in HbA1c and body weight and for the proportion of patients achieving reductions in both HbA1c and body weight. Odds ratios (ORs) and 95% CIs for the achievement of reductions in both HbA1c and body weight were also estimated. *P* values are reported for the prespecified comparison of percent change in body weight with canagliflozin versus glimepiride at Week 52 only. Statistical testing was not prespecified for efficacy comparisons at Week 104 or for the post hoc composite endpoint analyses; therefore, no *P* values are reported. Statistical analyses were performed using SAS, version 9.2 (Cary, NC, USA).

Compliance with Ethics {#Sec6}
----------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients included in the study.

Results {#Sec7}
=======

Patient Disposition and Baseline Characteristics {#Sec8}
------------------------------------------------

A total of 1450 subjects comprised the mITT and safety analysis sets; 71.0%, 66.6%, and 65.1% completed the 104-week, double-blind treatment period with canagliflozin 100 and 300 mg and glimepiride, respectively \[[@CR8]\]. Baseline demographic and disease characteristics were comparable across treatment groups, with a mean age of 56.2 years, HbA1c of 7.8%, and body mass index (BMI) of 31.0 kg/m^2^ (Table [1](#Tab1){ref-type="table"}). Mean metformin dose was 2177 mg/day; 62% of patients were taking metformin immediate release and 38% were taking metformin extended release. Among patients in the glimepiride group, 91.3% uptitrated over 104 weeks, with a mean maximum glimepiride dose of 5.8 mg and a mean final dose of 5.6 mg. Approximately 54% of subjects were considered to be obese (BMI ≥30 kg/m^2^), based upon National Institutes of Health criteria \[[@CR10]\].Table 1Baseline demographic and disease characteristics \[[@CR8]\]GLIM (*n* = 482)CANA 100 mg (*n* = 483)CANA 300 mg (*n* = 485)Sex, *n* (%) Male263 (55)252 (52)241 (50) Female219 (45)231 (48)244 (50)Mean ± SD age (years)56.3 ± 9.056.4 ± 9.555.8 ± 9.2Race, *n* (%) White322 (67)323 (67)333 (69) Black/African American22 (5)20 (4)18 (4) Asian93 (19)99 (21)93 (19) Other^a^45 (9)41 (8)41 (8)Mean ± SD body weight (kg)86.5 ± 19.886.9 ± 20.186.6 ± 19.5Mean ± SD body mass index (kg/m^2^)30.9 ± 5.531.0 ± 5.331.2 ± 5.4Mean ± SD HbA1c (%)7.8 ± 0.87.8 ± 0.87.8 ± 0.8Mean ± SD duration of T2DM (years)6.6 ± 5.06.5 ± 5.56.7 ± 5.5*CANA* canagliflozin, *GLIM* glimepiride, *SD* standard deviation, *T2DM* type 2 diabetes mellitus^a^Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, and other

Efficacy {#Sec9}
--------

Across all groups, there was a reduction from baseline in HbA1c at 52 and 104 weeks (Table [2](#Tab2){ref-type="table"}). The nadir in HbA1c was reached at Week 52 in both canagliflozin groups, with small increases thereafter; for glimepiride, the nadir in HbA1c was reached at Week 18, with a subsequent continual rise through Week 104 \[[@CR8]\]. Body weight decreased over 52 weeks and then remained stable through Week 104 in both canagliflozin groups, while body weight increased over 52 weeks in the glimepiride group and then remained stable through Week 104 (Table [2](#Tab2){ref-type="table"}) \[[@CR8]\].Table 2Summary of changes in HbA1c and body weight at Weeks 52 and 104Week 52 \[[@CR7]\]Week 104 \[[@CR8]\]GLIMCANA 100 mgCANA 300 mgGLIMCANA 100 mgCANA 300 mgLS mean change in HbA1c (%)--0.81--0.82--0.93--0.55--0.65--0.74 Difference vs GLIM (95% CI)--0.01 (--0.11, 0.09)--0.12 (--0.22, --0.02)--0.09 (--0.20, 0.01)--0.18 (--0.29, --0.08)LS mean % change in body weight1.0--4.2--4.70.9--4.1--4.2 Difference vs GLIM (95% CI)--5.2 (--5.7, --4.7)^a^--5.7 (--6.2, --5.1)^a^--5.1 (--5.6, --4.5)--5.2 (--5.7, --4.6)LS mean change in body weight (kg)0.7--3.7--4.00.8--3.6--3.6 Difference vs GLIM (95% CI)--4.4 (--4.8, --3.9)--4.7 (--5.2, --4.3)--4.3 (--4.8, --3.8)--4.4 (--4.9, --3.9)*CANA* canagliflozin, *CI* confidence interval, *GLIM* glimepiride, *LS* least squares^a^ *P* \< 0.001 vs GLIM

At Week 52, 72.4%, 78.5%, and 26.8% of patients achieved reductions in both HbA1c and body weight with canagliflozin 100 and 300 mg versus glimepiride, respectively (Fig. [1](#Fig1){ref-type="fig"}; Table [3](#Tab3){ref-type="table"}). Odds for achieving this composite endpoint favored canagliflozin 100 and 300 mg versus glimepiride \[ORs (95% CI) of 7.7 (5.7, 10.3) and 10.7 (7.9, 14.5), respectively\]. At Week 104, 65.5%, 71.1%, and 26.8% of patients achieved reductions in both HbA1c and body weight with canagliflozin 100 and 300 mg and glimepiride, respectively (Fig. [2](#Fig2){ref-type="fig"}; Table [3](#Tab3){ref-type="table"}). Odds for achieving this composite endpoint favored canagliflozin 100 and 300 mg versus glimepiride \[ORs (95% CI) of 5.6 (4.2, 7.5) and 7.4 (5.5, 9.8), respectively\].Fig. 1Change in both HbA1c and body weight with **a** CANA 100 mg and **b** CANA 300 mg versus GLIM at Week 52. *CANA* canagliflozin, *GLIM* glimepirideTable 3Proportion of patients with both HbA1c and body weight reduction at Weeks 52 and 104GLIM (*n* = 474)CANA 100 mg (*n* = 478)CANA 300 mg (*n* = 474)Week 52 Patients, *n* (%)127 (26.8)346 (72.4)372 (78.5)  Difference vs GLIM (95% CI)45.6 (39.7, 51.5)51.7 (46.0, 57.3)  OR vs GLIM (95% CI)7.7 (5.7, 10.3)10.7 (7.9, 14.5)Week 104 Patients, *n* (%)127 (26.8)313 (65.5)337 (71.1)  Difference vs GLIM (95% CI)38.7 (32.6, 44.7)44.3 (38.4, 50.2)  OR vs GLIM (95% CI)5.6 (4.2, 7.5)7.4 (5.5, 9.8)*CANA* canagliflozin, *CI* confidence interval, *GLIM* glimepiride, *OR* odds ratioFig. 2Change in both HbA1c and body weight with **a** CANA 100 mg and **b** CANA 300 mg versus GLIM at Week 104. *CANA* canagliflozin, *GLIM* glimepiride

Safety {#Sec10}
------

Details of the safety of canagliflozin 100 and 300 mg versus glimepiride over 104 weeks have been previously reported \[[@CR8]\]. Briefly, the overall incidence of AEs was 73.3%, 77.9%, and 78.4% with canagliflozin 100 and 300 mg and glimepiride, respectively; the incidence of AEs leading to discontinuation was 6.2%, 9.5%, and 7.3%, respectively, and the incidence of serious AEs was 9.7%, 9.7%, and 14.3%, respectively. Incidences of genital mycotic infections in men (9.5% and 9.1% vs 1.9%) and women (13.9% and 15.6% vs 2.7%), urinary tract infections (10.6% and 8.7% vs 6.8%), and AEs related to osmotic diuresis (5.8% and 6.6% vs 2.1%) were higher with canagliflozin 100 and 300 mg versus glimepiride. At Week 104, the incidence of documented hypoglycemia was lower with canagliflozin 100 and 300 mg versus glimepiride (6.8% and 8.2% vs 40.9%). The frequency of severe hypoglycemic episodes was 0.6% (*n* = 3), 0.2% (*n* = 1), and 3.3% (*n* = 16) with canagliflozin 100 and 300 mg and glimepiride, respectively.

Discussion {#Sec11}
==========

In this post hoc analysis, patients with T2DM inadequately controlled with metformin who were treated with canagliflozin were more likely to achieve improved glycemic control (as evidenced by lower HbA1c) and concomitant weight loss than those treated with glimepiride at 52 and 104 weeks. Canagliflozin was well tolerated with an AE profile comparable to that previously documented in other studies, including increased incidence of genital mycotic infections, urinary tract infections, and AEs related to osmotic diuresis \[[@CR4]\]. In addition, canagliflozin was associated with lower rates of hypoglycemia compared with glimepiride, including a low risk of severe episodes, over 104 weeks.

Glycemic improvements, weight loss, and low risk of hypoglycemia have also been reported with the SGLT2 inhibitors dapagliflozin and empagliflozin in patients with T2DM on background metformin versus sulfonylurea \[[@CR11]--[@CR14]\]. Composite endpoint analyses of reduction in both HbA1c and body weight have been reported with dapagliflozin, but not empagliflozin, and results were generally consistent with the present study. In a 52-week study of dapagliflozin versus glipizide as add-on to metformin, a higher proportion of patients achieved reductions in both HbA1c and body weight with dapagliflozin versus glipizide (66.9% vs 21.3%) \[[@CR15]\]. Overall, findings with canagliflozin and dapagliflozin demonstrate that SGLT2 inhibitors may provide better achievement of both HbA1c and weight loss compared with sulfonylureas in patients with T2DM.

A previous study suggested that \~40% of patients with T2DM who are receiving metformin monotherapy and add a sulfonylurea to their treatment regimen will gain weight in the year following intensification of therapy \[[@CR3]\]. Additionally, with every increase in BMI category (from normal to severely obese), the rate of hospitalizations for cardiovascular disease, stroke, amputation, blindness, and end-stage renal disease rose \[[@CR3]\]. Thus, in addition to improvements in glycemic control, the reductions in body weight provided by canagliflozin make it a promising treatment option for patients with T2DM who are overweight or obese. The benefits of weight loss on other diabetes-related outcomes with canagliflozin have been demonstrated in an analysis of pooled data from 4 randomized, double-blind, placebo-controlled trials in which \~15% of HbA1c lowering and \~40% of systolic blood pressure lowering was associated with weight loss; thus, each 1% reduction in body weight was associated with a 0.045% decrease in HbA1c and a 0.62 mmHg reduction in systolic blood pressure \[[@CR16]\]. Indeed, a reduction of 5--10% in body weight in patients with T2DM is associated with beneficial effects on glycemia, blood pressure, high-density lipoprotein cholesterol (HDL-C), and triglycerides \[[@CR17]\]. However, it is unknown whether these benefits will translate to improvement in long-term clinical outcomes, including cardiovascular disease. Patients with T2DM with pre-existing cardiovascular disease who had reductions in HbA1c, body weight, and blood pressure with the SGLT2 inhibitor empagliflozin were shown to have decreased risk of cardiovascular events and mortality \[[@CR18]\]. The ongoing CANagliflozin cardioVascular Assessment Study (CANVAS; ClinicalTrials.gov Identifier: NCT01032629) and CANVAS-R (renal endpoints; NCT01989754) trials will evaluate the long-term efficacy and safety, including cardiovascular outcomes, of canagliflozin in patients with T2DM and a history or high risk of cardiovascular disease \[[@CR19]\].

Conclusion {#Sec12}
==========

In summary, canagliflozin provided greater attainment of reductions in both HbA1c and body weight compared with glimepiride at Weeks 52 and 104, and was generally well tolerated in patients with T2DM when used as adjunctive therapy to metformin.
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